Multi-omics Approaches to CCAAT/Enhancer-Binding Protein Beta in Oral Squamous Cell Carcinoma: Crosstalk Between Tumor Cells and Tumor-Associated Macrophages Driving Disease Progression.
{"title":"Multi-omics Approaches to CCAAT/Enhancer-Binding Protein Beta in Oral Squamous Cell Carcinoma: Crosstalk Between Tumor Cells and Tumor-Associated Macrophages Driving Disease Progression.","authors":"Min Li, Jilun Liu, Wenjuan Zhang, Ruonan Sun, Wenjing Wang, Xin Liu, Linyu Jin, Yongle Qiu","doi":"10.2174/0115680096387374250823190214","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>CCAAT/Enhancer-Binding Protein Beta (CEBPB) is an important transcription factor that regulates tumor progression. However, the mechanism by which CE-BPB regulates the progression of Oral Squamous Cell Carcinoma (OSCC) remains incom-pletely understood. Tumor progression depends on complex intercellular interactions within the tumor microenvironment. The purpose of this study was to investigate the role and epige-netic regulatory mechanisms of CEBPB in interactions between OSCC cells and tumor-infil-trating immune cells.</p><p><strong>Methods: </strong>Bulk RNA-seq, ChIP-seq, and scRNA-seq data were obtained from The Cancer Ge-nome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The HOMER algorithm was employed to identify enhancers and predict the CEBPB-binding mo-tif. Cell cluster analysis, functional enrichment, and intercellular interaction analysis were per-formed using the \"Seurat\" R package. H3K27ac enrichment at GAS6 enhancers was validated by ChIP-qPCR. Metastatic OSCC cells with CEBPB knockdown or GAS6 overexpression were established and co-cultured with THP-1 cells. IL-10 and IL-6 secretion from co-cultured THP-1 cells was detected via ELISA. Chemotaxis of OSCC cells toward THP-1 cells was assessed through a Transwell assay.</p><p><strong>Results: </strong>CEBPB was upregulated in OSCC and correlated with poor prognosis. By integrating H3K27ac ChIP-seq and bulk RNA-seq data, 131 CEBPB-regulated enhancer-controlled genes were identified in lymph node metastatic OSCC cells. scRNA-seq analysis revealed eight ma-jor cell clusters in primary foci and lymph node metastases, including T/NK cells, malignant epithelial cells, B/plasma cells, macrophages, fibroblasts, dendritic cells, endothelial cells, and mast cells, with the malignant epithelial cells stratified into distinct sub-clusters. CEBPB ex-pression was elevated in malignant epithelial cells of lymph node metastases compared to pri-mary foci. Furthermore, 15 pairs of enhanced ligand-receptor interactions were identified in lymph node metastases relative to primary foci. GAS6 was a CEBPB-regulated enhancer-con-trolled gene, primarily mediating interactions between malignant cells and macrophages. CE-BPB knockdown in metastatic OSCC cells significantly impaired their chemotaxis toward co-cultured THP-1 cells, and downregulated IL-10/IL-6 secretion and CD206 expression in co-cultured THP-1 cells. Conversely, GAS6 overexpression reversed these inhibitory effects.</p><p><strong>Conclusion: </strong>CEBPB activated GAS6 transcription in metastatic OSCC cells. The CE-BPB/GAS6 axis in metastatic OSCC cells enhanced their chemotaxis toward macrophages and promoted the M2 polarization of macrophages, thereby facilitating the establishment of an immunosuppressive microenvironment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096387374250823190214","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: CCAAT/Enhancer-Binding Protein Beta (CEBPB) is an important transcription factor that regulates tumor progression. However, the mechanism by which CE-BPB regulates the progression of Oral Squamous Cell Carcinoma (OSCC) remains incom-pletely understood. Tumor progression depends on complex intercellular interactions within the tumor microenvironment. The purpose of this study was to investigate the role and epige-netic regulatory mechanisms of CEBPB in interactions between OSCC cells and tumor-infil-trating immune cells.
Methods: Bulk RNA-seq, ChIP-seq, and scRNA-seq data were obtained from The Cancer Ge-nome Atlas (TCGA) database and the Gene Expression Omnibus (GEO) database. The HOMER algorithm was employed to identify enhancers and predict the CEBPB-binding mo-tif. Cell cluster analysis, functional enrichment, and intercellular interaction analysis were per-formed using the "Seurat" R package. H3K27ac enrichment at GAS6 enhancers was validated by ChIP-qPCR. Metastatic OSCC cells with CEBPB knockdown or GAS6 overexpression were established and co-cultured with THP-1 cells. IL-10 and IL-6 secretion from co-cultured THP-1 cells was detected via ELISA. Chemotaxis of OSCC cells toward THP-1 cells was assessed through a Transwell assay.
Results: CEBPB was upregulated in OSCC and correlated with poor prognosis. By integrating H3K27ac ChIP-seq and bulk RNA-seq data, 131 CEBPB-regulated enhancer-controlled genes were identified in lymph node metastatic OSCC cells. scRNA-seq analysis revealed eight ma-jor cell clusters in primary foci and lymph node metastases, including T/NK cells, malignant epithelial cells, B/plasma cells, macrophages, fibroblasts, dendritic cells, endothelial cells, and mast cells, with the malignant epithelial cells stratified into distinct sub-clusters. CEBPB ex-pression was elevated in malignant epithelial cells of lymph node metastases compared to pri-mary foci. Furthermore, 15 pairs of enhanced ligand-receptor interactions were identified in lymph node metastases relative to primary foci. GAS6 was a CEBPB-regulated enhancer-con-trolled gene, primarily mediating interactions between malignant cells and macrophages. CE-BPB knockdown in metastatic OSCC cells significantly impaired their chemotaxis toward co-cultured THP-1 cells, and downregulated IL-10/IL-6 secretion and CD206 expression in co-cultured THP-1 cells. Conversely, GAS6 overexpression reversed these inhibitory effects.
Conclusion: CEBPB activated GAS6 transcription in metastatic OSCC cells. The CE-BPB/GAS6 axis in metastatic OSCC cells enhanced their chemotaxis toward macrophages and promoted the M2 polarization of macrophages, thereby facilitating the establishment of an immunosuppressive microenvironment.
背景:CCAAT/增强子结合蛋白β (CEBPB)是调节肿瘤进展的重要转录因子。然而,CE-BPB调节口腔鳞状细胞癌(OSCC)进展的机制仍不完全清楚。肿瘤的进展取决于肿瘤微环境中复杂的细胞间相互作用。本研究旨在探讨CEBPB在OSCC细胞与肿瘤浸润免疫细胞相互作用中的作用及其表观遗传学调控机制。方法:从The Cancer ge - name Atlas (TCGA)数据库和Gene Expression Omnibus (GEO)数据库中获取Bulk RNA-seq、ChIP-seq和scRNA-seq数据。采用HOMER算法识别增强子并预测cebpb结合基序。使用“Seurat”R包进行细胞聚类分析、功能富集和细胞间相互作用分析。通过ChIP-qPCR验证了H3K27ac在GAS6增强子上的富集。建立CEBPB敲低或GAS6过表达的转移性OSCC细胞,并与THP-1细胞共培养。ELISA法检测共培养THP-1细胞IL-10和IL-6的分泌情况。通过Transwell实验评估OSCC细胞对THP-1细胞的趋化性。结果:CEBPB在OSCC中表达上调,与预后不良相关。通过整合H3K27ac ChIP-seq和大量RNA-seq数据,在淋巴结转移性OSCC细胞中鉴定出131个cebpb调控的增强子控制基因。scRNA-seq分析显示原发灶和淋巴结转移中有8个主要的细胞簇,包括T/NK细胞、恶性上皮细胞、B/浆细胞、巨噬细胞、成纤维细胞、树突状细胞、内皮细胞和肥大细胞,其中恶性上皮细胞分为不同的亚簇。与原发灶相比,淋巴结转移的恶性上皮细胞中CEBPB表达升高。此外,与原发病灶相比,在淋巴结转移中发现了15对增强的配体-受体相互作用。GAS6是cebpb调控的增强子控制基因,主要介导恶性细胞和巨噬细胞之间的相互作用。CE-BPB敲低显著降低转移性OSCC细胞对共培养THP-1细胞的趋化性,下调共培养THP-1细胞中IL-10/IL-6分泌和CD206表达。相反,GAS6过表达逆转了这些抑制作用。结论:CEBPB激活了转移性OSCC细胞中GAS6的转录。转移性OSCC细胞的CE-BPB/GAS6轴增强了其对巨噬细胞的趋化性,促进了巨噬细胞的M2极化,从而促进了免疫抑制微环境的建立。
期刊介绍:
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.